Adherence and variability in warfarin dose requirements: Assessment in a prospective cohort

Pharmacogenomics

Volumn 14, Issue 2, 2013, Pages 151-163

  Jorgensen, Andrea L ^a   Hughes, Dyfrig A ^b   Hanson, Anita ^a   Van Eker, Diane ^a   Toh, Cheng Hock ^c   Pirmohamed, Munir ^a   Williamson, Paula R ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

adherence; anticoagulation; pharmacogenetics; pharmacogenomics; warfarin

Indexed keywords

WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DOSE REQUIREMENT; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACOGENETICS; PHARMACOLOGICAL PARAMETERS; PROSPECTIVE STUDY; PROSTHETIC VALVE THROMBOSIS; QUESTIONNAIRE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGRESSION ANALYSIS; TREATMENT OUTCOME; WARFARIN; YOUNG ADULT;

EID: 84872579569     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.199     Document Type: Article

References (39)

1. Dodd S, White IR, Williamson PR. Nonadherence to treatment protocol in published randomised controlled trials: a review. Trials 13, 84 (2012).
2. Sheiner LB. Is intent-to-treat analysis always (ever) enough? Br. J. Clin. Pharmacol. 54(2), 203-211 (2002). (Pubitemid 35024945)
3. Osterberg L, Blaschke T. Adherence to Medication. N. Engl. J. Med. 353(5), 487-497 (2005). (Pubitemid 41127293)
4. Lim LL. Estimating compliance to study medication from serum drug levels: application to an AIDS clinical trial of zidovudine. Biometrics 48(2), 619-630 (1992).
5. Dusing R, Lottermoser K, Mengden T. Compliance with drug therapy-new answers to an old question. Nephrol. Dial. Transplant. 16(7), 1317-1321 (2001). (Pubitemid 32640580)
6. Vrijens B, Tousset E, Rode R, Bertz R, Mayer S, Urquhart J. Successful projection of the time course of drug concentration in plasma during a 1-year period from electronically compiled dosing-time data used as input to individually parameterized pharmacokinetic models. J. Clin. Pharmacol. 45(4), 461-467 (2005). (Pubitemid 40490419)
7. Shi L, Liu J, Fonseca V, Walker P, Kalsekar A, Pawaskar M. Correlation between adherence rates measured by MEMS and self-reported questionnaires: a meta-analysis. Health Qual Life Outcomes 8, 99 (2010).
8. Shi L, Liu J, Koleva Y, Fonseca V, Kalsekar A, Pawaskar M. Concordance of adherence measurement using self-reported adherence questionnaires and medication monitoring devices. Pharmacoeconomics 28(12), 1097-1107 (2010).
9. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med. 323(22), 1505-1511 (1990).
10. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342(8882), 1255-1262 (1993).
11. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348(9028), 633-638 (1996).
12. Burns M. Management of narrow therapeutic index drugs. J. Thromb. Thrombolysis 7(2), 137-143 (1999). (Pubitemid 29224993)
13. Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 7(2), 99-111 (2007). (Pubitemid 46567142)
14. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4(1), 39-42 (1994). (Pubitemid 24106122)
15. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys 333(2), 447-458 (1996). (Pubitemid 26304913)
16. D'Andrea G, D'Ambrosio RL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2), 645-649 (2005). (Pubitemid 40070748)
17. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005). (Pubitemid 40740552)
18. Jorgensen AL, Al-Zubiedi S, Zhang JE et al. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet. Genomics 19(10), 800-812 (2009).
19. Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23-34 (2007). (Pubitemid 46421137)
20. Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106(7), 2329-2333 (2005). (Pubitemid 41510803)
21. Aquilante CL, Langaee TY, Lopez LM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4), 291-302 (2006).
22. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost. 95(5), 782-787 (2006).
23. Tham LS, Goh BC, Nafziger A et al. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80(4), 346-355 (2006). (Pubitemid 44479750)
24. Carlquist JF, Horne BD, Muhlestein JB et al. Genotypes of the cytochrome P450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22(3), 191-197 (2006). (Pubitemid 44857780)
25. Kimura R, Miyashita K, Kokubo Y et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120(2), 181-186 (2007). (Pubitemid 46754413)
26. Zhu Y, Shennan M, Reynolds KK et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53(7), 1199-1205 (2007). (Pubitemid 47020974)
27. Wu AHB, Wang P, Smith A et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9(2), 169-178 (2008). (Pubitemid 351566941)
28. Gage B, Eby C, Johnson J et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
29. Kimmel SE, Chen Z, Price M et al. The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio adherence and genetics (IN-RANGE) study. Arch. Intern. Med. 167(3), 229-235 (2007).
30. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ. Couns. 37(2), 113-124 (1999). (Pubitemid 29276860)
31. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann. Intern. Med. 124, 970-979 (1996).
32. Choo PW, Rand CS, Inui TS et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med. Care 37(9), 846-857 (1999).
33. Curtin RB, Svarstad BL, Keller TH. Hemodialysis patients' noncompliance with oral medications. ANNA J. 26(3), 307-316; discussion 317, 335 (1999).
34. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. Clin. Ther. 27(2), 199-209 (2005). (Pubitemid 40462013)
35. R Development Core Team. R: a Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2012).
36. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statistic. Soc. B 57(1), 289-300 (1995).
37. Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: issues of concern. Stat. Med. 27(30), 6547-6569 (2008).
38. Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin. Pharmacol. Ther. 88(4), 457-459 (2010).
39. McClain MR, Palomaki GE, Piper M, Haddow JE. A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet. Med. 10(2), 89-98 (2008). (Pubitemid 351271719)